Curi Bio Raises $10M Series B to Scale Human iPSC Platforms for Drug Discovery
核心洞察
Curi Bio (搜索) secured $10 million in Series B funding led by DreamCIS (搜索) to expand its human iPSC-derived cell platforms for drug discovery and development.
The company's integrated platform combines human iPSC-derived cells, tissue-specific biosystems, and advanced data analysis to address high clinical trial failure rates.
Funding will accelerate development of new platforms targeting cardiac, skeletal muscle, metabolic, smooth muscle, and neuromuscular diseases (搜索) including ALS (搜索).
Curi Bio (搜索), a Seattle-based biotechnology company specializing in human-relevant functional data for drug discovery, announced the completion of a $10 million Series B financing round led by DreamCIS (搜索), a leading contract research organization based in Seoul, South Korea. The strategic partnership aims to accelerate the global translation of Curi Bio's human-relevant platforms into clinical success.
The funding will directly support the scaling of Curi Bio (搜索)'s integrated platforms featuring human iPSC-derived cells, tissue-specific biosystems, and advanced data analysis capabilities. The investment will accelerate development of new platforms targeting cardiac, skeletal muscle, metabolic, smooth muscle, and neuromuscular diseases (搜索) while expanding the company's commercial reach globally.
Addressing Drug Development's Critical Challenge
Curi Bio (搜索) is tackling one of drug development's most persistent problems: high clinical trial failure rates and the enormous time and cost required to bring new therapeutics to market. According to the company, the vast majority of new drugs fail in human clinical trials because preclinical animal and 2D cell models have failed to be good predictors of human outcomes.
"Curi has seen great success in de-risking our client's drug development and manufacturing. The data we deliver have been critical in guiding candidate selection, getting our clients to IND, and driving decisions on potency; all using advanced human functional models that surpass legacy animal models in precision and accuracy," said Nicholas A. Geisse, PhD, CEO of Curi Bio (搜索).
The company's bioengineered approach provides clinically-relevant human data far earlier in the discovery process through a unique three-pronged platform strategy that integrates high-purity, next-generation human iPSC-derived cells with advanced biosystems that mature cells into 3D engineered tissues and measure complex functional data, combined with in-depth analysis that uncovers key functional phenotypic insights.
Strategic Partnership and Market Positioning
The partnership with DreamCIS (搜索) reflects a broader industry shift toward human-relevant functional data in early-stage drug development. Elliot Fisher, Co-founder and Chief Business Officer of Curi Bio (搜索), noted that "drug developers are demanding human-relevant functional data earlier, because traditional animal and 2D models aren't predicting human outcomes. Curi has spent nearly a decade commercializing the platforms needed to close that gap."
Jeounghee Yoo, CEO of DreamCIS (搜索), emphasized the transformative potential of Curi Bio (搜索)'s technology: "Curi Bio's unique integration of cells, systems, and data is a paradigm shift for preclinical drug discovery. We were incredibly impressed by the company's innovative platforms and their ability to generate functional data from 3D human tissues at scale. This technology provides the predictive power that pharma companies desperately need to improve R&D productivity."
Therapeutic Focus Areas
The expanded platforms will target multiple disease areas where current preclinical models have shown limitations. Geisse highlighted the company's focus on "devastating diseases like muscle metabolism and wasting (搜索), neuromuscular diseases (搜索) like ALS (搜索), cardiac indications, and beyond." The data delivered through Curi Bio (搜索)'s products and services aims to de-risk R&D pipelines and accelerate the development of safer, more effective medicines for patients.
Michael Cho, JD, Chief Strategy Officer at Curi Bio (搜索), emphasized the urgent need for improved preclinical models: "We are thrilled to partner with DreamCIS (搜索), who shares our conviction that drug discovery urgently needs more human-relevant data at the preclinical stage."
The company positions itself as bridging the gap between preclinical R&D and clinical outcomes through its integrated platform of advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and advanced automated data analysis capabilities.